Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
TECH Quote, Financials, Valuation and Earnings
Last price:
$59.23
Seasonality move
:
4.15%
Day range:
$58.77 - $59.34
52-week range:
$46.01 - $79.28
Dividend yield:
0.54%
P/E ratio:
121.05x
P/S ratio:
7.68x
P/B ratio:
4.69x
Volume:
584.9K
Avg. volume:
1.8M
1-year change:
-19.11%
Market cap:
$9.2B
Revenue:
$1.2B
EPS (TTM):
$0.49
Analysts' Opinion
-
Consensus RatingBio-Techne Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $69.67, Bio-Techne Corp. has an estimated upside of 17.64% from its current price of $59.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $60.00 representing 100% downside risk from its current price of $59.22.
Fair Value
-
According to the consensus of 14 analysts, Bio-Techne Corp. has 17.64% upside to fair value with a price target of $69.67 per share.
TECH vs. S&P 500
-
Over the past 5 trading days, Bio-Techne Corp. has overperformed the S&P 500 by 2.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bio-Techne Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Techne Corp. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Techne Corp. reported revenues of $286.6M.
Earnings Growth
-
Bio-Techne Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bio-Techne Corp. reported earnings per share of $0.24.
Enterprise value:
9.5B
EV / Invested capital:
--
Price / LTM sales:
7.68x
EV / EBIT:
35.58x
EV / Revenue:
7.79x
PEG ratio (5yr expected):
--
EV / Free cash flow:
42.30x
Price / Operating cash flow:
41.68x
Enterprise value / EBITDA:
25.44x
Gross Profit (TTM):
$812.6M
Return On Assets:
2.97%
Net Income Margin (TTM):
6.41%
Return On Equity:
3.85%
Return On Invested Capital:
3.2%
Operating Margin:
17.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.2B | $1.2B | $289.5M | $286.6M | |
| Gross Profit | $775.4M | $775.8M | $812.6M | $187.9M | $190.2M | |
| Operating Income | $276.9M | $244.7M | $266.4M | $51M | $50.8M | |
| EBITDA | $386.1M | $356M | $372.5M | $79.1M | $75.1M | |
| Diluted EPS | $1.52 | $0.94 | $0.49 | $0.21 | $0.24 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $543.7M | $552M | $591.5M | $648.6M | $609.5M | |
| Total Assets | $2.3B | $2.4B | $2.8B | $2.7B | $2.5B | |
| Current Liabilities | $134M | $137.6M | $127.8M | $142.1M | $144.5M | |
| Total Liabilities | $623.2M | $599.6M | $757.6M | $597.4M | $560.3M | |
| Total Equity | $1.6B | $1.8B | $2B | $2.1B | $2B | |
| Total Debt | $365.3M | $329.4M | $537.3M | $385.4M | $380.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $257.7M | $303.5M | $251.3M | $63.9M | $27.6M | |
| Cash From Investing | -$400.1M | -$70.6M | -$12.9M | -$21.7M | $605K | |
| Cash From Financing | $125.9M | -$205.5M | -$286.5M | -$11.6M | -$44.2M | |
| Free Cash Flow | $215.4M | $245M | $224.1M | $54.7M | $22.2M | |
TECH
Sector
Market Cap
$9.2B
$28.2M
Price % of 52-Week High
74.7%
51.2%
Dividend Yield
0.54%
0%
Shareholder Yield
3.24%
-1.54%
1-Year Price Total Return
-19.12%
-18.1%
Beta (5-Year)
1.464
0.516
Dividend yield:
0.54%
Annualized payout:
$0.32
Payout ratio:
32.76%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$58.30
200-day SMA
Buy
Level
$55.21
Bollinger Bands (100)
Buy
Level
53.52 - 62.2
Chaikin Money Flow
Sell
Level
-184.5K
20-day SMA
Sell
Level
$60.20
Relative Strength Index (RSI14)
Sell
Level
47.35
ADX Line
Buy
Level
27.76
Williams %R
Neutral
Level
-48.4314
50-day SMA
Sell
Level
$60.96
MACD (12, 26)
Buy
Level
16.07
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
5.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.0755)
Buy
CA Score
(Annual)
Level (1.2505)
Buy
Beneish M-Score
(Annual)
Level (-3.0914)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.4425)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Spatial Biology segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Stock Forecast FAQ
In the current month, TECH has received 11 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TECH average analyst price target in the past 3 months is $69.67.
-
Where Will Bio-Techne Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Techne Corp. share price will rise to $69.67 per share over the next 12 months.
-
What Do Analysts Say About Bio-Techne Corp.?
Analysts are divided on their view about Bio-Techne Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Techne Corp. is a Sell and believe this share price will drop from its current level to $60.00.
-
What Is Bio-Techne Corp.'s Price Target?
The price target for Bio-Techne Corp. over the next 1-year time period is forecast to be $69.67 according to 14 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is TECH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Techne Corp. is a Buy. 11 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TECH?
You can purchase shares of Bio-Techne Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Techne Corp. shares.
-
What Is The Bio-Techne Corp. Share Price Today?
Bio-Techne Corp. was last trading at $59.23 per share. This represents the most recent stock quote for Bio-Techne Corp.. Yesterday, Bio-Techne Corp. closed at $59.22 per share.
-
How To Buy Bio-Techne Corp. Stock Online?
In order to purchase Bio-Techne Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TECH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TECH
Sector
P/E ratio
121.05x
23.92x
PEG ratio
--
-0.01x
P/B ratio
4.69x
1.83x
Price / LTM sales
7.68x
1.61x
Growth Metrics
TECH
Sector
Revenue growth
-1%
4.6%
Earnings growth
17.12%
10.88%
Revenue (5-year growth)
10.55%
6.46%
Earnings forecast
$0.56
-$0.21
Profitability
TECH
Sector
Profitability FY 2025
$779M
$3.5M
Return on invested capital
3.2%
-31.84%
Return on assets
2.97%
-27.96%
Return on equity
3.85%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
9
Estimated Next Earnings Date
Feb
4
Balance Sheet
TECH
Sector
Total cash
$145M
$26.3M
Short term investments
--
$25.7M
Total assets
$2.6B
$76.9M
Long term debt
$380.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
